These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 22580535)

  • 21. Functional polymorphisms and methotrexate treatment outcome in recent-onset rheumatoid arthritis.
    Kooloos WM; Wessels JA; van der Straaten T; Allaart CF; Huizinga TW; Guchelaar HJ
    Pharmacogenomics; 2010 Feb; 11(2):163-75. PubMed ID: 20136356
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cotreatment with methotrexate in routine care patients with rheumatoid arthritis receiving biological treatment yields better outcomes over time.
    Boone NW; Sepriano A; van der Kuy PH; Janknegt R; Peeters R; Landewé RBM
    RMD Open; 2019; 5(1):e000836. PubMed ID: 30740244
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Multidrug resistance protein-1 expression, function and polymorphisms in patients with rheumatoid arthritis not responding to methotrexate.
    Prasad S; Tripathi D; Rai MK; Aggarwal S; Mittal B; Agarwal V
    Int J Rheum Dis; 2014 Nov; 17(8):878-86. PubMed ID: 24734954
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Associations between the genetic polymorphisms of MTHFR and outcomes of methotrexate treatment in rheumatoid arthritis.
    Xiao H; Xu J; Zhou X; Stankovich J; Pan F; Zhang Z; Xu S; Lian L; Ding C
    Clin Exp Rheumatol; 2010; 28(5):728-33. PubMed ID: 20863444
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Association of C35T polymorphism in dihydrofolate reductase gene with toxicity of methotrexate in rheumatoid arthritis patients.
    Vejnović D; Milić V; Popović B; Damnjanović T; Maksimović N; Bunjevački V; Krajinović M; Novaković I; Damjanov N; Jekić B
    Expert Opin Drug Metab Toxicol; 2019 Mar; 15(3):253-257. PubMed ID: 30583708
    [TBL] [Abstract][Full Text] [Related]  

  • 26. IL-1B and IL-1RN gene polymorphisms in rheumatoid arthritis: relationship with protein plasma levels and response to therapy.
    Tolusso B; Pietrapertosa D; Morelli A; De Santis M; Gremese E; Farina G; Carniello SG; Del Frate M; Ferraccioli G
    Pharmacogenomics; 2006 Jul; 7(5):683-95. PubMed ID: 16886894
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Methylenetetrahydrofolate reductase polymorphisms and methotrexate: no association with response to therapy nor with drug-related adverse events in an Italian population of rheumatic patients.
    Taraborelli M; Andreoli L; Archetti S; Ferrari M; Cattaneo R; Tincani A
    Clin Exp Rheumatol; 2009; 27(3):499-502. PubMed ID: 19604445
    [TBL] [Abstract][Full Text] [Related]  

  • 28. ABCB1 C3435T polymorphism influences methotrexate sensitivity in rheumatoid arthritis patients.
    Takatori R; Takahashi KA; Tokunaga D; Hojo T; Fujioka M; Asano T; Hirata T; Kawahito Y; Satomi Y; Nishino H; Tanaka T; Hirota Y; Kubo T
    Clin Exp Rheumatol; 2006; 24(5):546-54. PubMed ID: 17181924
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The impact of C677T and A1298C MTHFR polymorphisms on methotrexate therapeutic response in East Bohemian region rheumatoid arthritis patients.
    Soukup T; Dosedel M; Pavek P; Nekvindova J; Barvik I; Bubancova I; Bradna P; Kubena AA; Carazo AF; Veleta T; Vlcek J
    Rheumatol Int; 2015 Jul; 35(7):1149-61. PubMed ID: 25618758
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Association of the TYMS 3G/3G genotype with poor response and GGH 354GG genotype with the bone marrow toxicity of the methotrexate in RA patients.
    Jekic B; Lukovic L; Bunjevacki V; Milic V; Novakovic I; Damnjanovic T; Milasin J; Popovic B; Maksimovic N; Damjanov N; Radunovic G; Kovacevic L; Krajinovic M
    Eur J Clin Pharmacol; 2013 Mar; 69(3):377-83. PubMed ID: 22763757
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Membrane-Spanning Protein Genetic Polymorphisms Related to Methotrexate Therapeutic Outcomes in a Chinese Rheumatoid Arthritis Population.
    Lv S; Fan H; Yang H; Huang J; Li J; Shu X; Zhang L; Xu Y; Li X; Zuo J; Lv C; Kong X; Xiao C
    J Clin Pharmacol; 2019 Nov; 59(11):1471-1476. PubMed ID: 31099054
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Association of the ATIC 347 C/G polymorphism with responsiveness to and toxicity of methotrexate in rheumatoid arthritis: a meta-analysis.
    Lee YH; Bae SC
    Rheumatol Int; 2016 Nov; 36(11):1591-1599. PubMed ID: 27379764
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Genetic polymorphisms in folate pathway enzymes as a possible marker for predicting the outcome of methotrexate therapy in Japanese patients with rheumatoid arthritis.
    Hayashi H; Fujimaki C; Daimon T; Tsuboi S; Matsuyama T; Itoh K
    J Clin Pharm Ther; 2009 Jun; 34(3):355-61. PubMed ID: 19827168
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Endogenous estradiol and its association with estrogen receptor gene polymorphisms.
    Sowers MR; Jannausch ML; McConnell DS; Kardia SR; Randolph JF
    Am J Med; 2006 Sep; 119(9 Suppl 1):S16-22. PubMed ID: 16949384
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Common polymorphisms in the folate pathway predict efficacy of combination regimens containing methotrexate and sulfasalazine in early rheumatoid arthritis.
    James HM; Gillis D; Hissaria P; Lester S; Somogyi AA; Cleland LG; Proudman SM
    J Rheumatol; 2008 Apr; 35(4):562-71. PubMed ID: 18322994
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Analysis of association of ADORA
    Grk M; Milic V; Dolzan V; Maksimovic N; Damnjanovic T; Pjevic MD; Pesic M; Novakovic I; Jekic B
    Pharmacogenomics J; 2020 Dec; 20(6):784-791. PubMed ID: 32448869
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The association between reduced folate carrier-1 gene 80G/A polymorphism and methotrexate efficacy or methotrexate related-toxicity in rheumatoid arthritis: A meta-analysis.
    Li X; Hu M; Li W; Gu L; Chen M; Ding H; Vanarsa K; Du Y
    Int Immunopharmacol; 2016 Sep; 38():8-15. PubMed ID: 27233001
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Association of a Type 2-Polarized T Cell Phenotype With Methotrexate Nonresponse in Patients With Rheumatoid Arthritis.
    Slauenwhite D; McAlpine SM; Hanly JG; Malik A; Haidl ID; Marshall JS; Issekutz TB
    Arthritis Rheumatol; 2020 Jul; 72(7):1091-1102. PubMed ID: 32039570
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Correlation between methotrexate efficacy & toxicity with C677T polymorphism of the methylenetetrahydrofolate gene in rheumatoid arthritis patients on folate supplementation.
    Aggarwal P; Naik S; Mishra KP; Aggarwal A; Misra R
    Indian J Med Res; 2006 Nov; 124(5):521-6. PubMed ID: 17213520
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prediction of DAS28-ESR remission at 6 months by baseline variables in patients with rheumatoid arthritis treated with etanercept in Japanese population.
    Iwamoto N; Kawakami A; Fujikawa K; Aramaki T; Kawashiri SY; Tamai M; Arima K; Ichinose K; Kamachi M; Yamasaki S; Nakamura H; Nakashima M; Mizokami A; Goto A; Fukuda T; Matsuoka N; Ueki Y; Tsukada T; Migita K; Shoumura F; Kawabe Y; Shibatomi K; Mine M; Ida H; Origuchi T; Aoyagi K; Eguchi K
    Mod Rheumatol; 2009; 19(5):488-92. PubMed ID: 19578932
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.